SCHAFER GREGORY W 4

4 · ADURO BIOTECH, INC. · Filed Nov 8, 2017

Form 4

Period: 2017-11-06

Chief Operating Officer

Transactions

Exercise/Conversion
Common Stock
2017-11-06$1.45/sh+6,932$10,051→ 155,677 total
Exercise/Conversion
Common Stock
2017-11-06$0.82/sh+13,068$10,716→ 168,745 total
Exercise/Conversion
Stock Option (right to buy)
2017-11-06−6,932→ 106,676 total
Exercise: $1.45Exp: 2025-01-09→ Common Stock (6,932 underlying)
Exercise/Conversion
Stock Option (right to buy)
2017-11-06−13,068→ 215,459 total
Exercise: $0.82Exp: 2023-11-26→ Common Stock (13,068 underlying)
Sale
Common Stock
2017-11-06$7.97/sh−20,000$159,312→ 148,745 total

Footnotes (4)

[F1]The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2017.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 to $8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F3]The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015.
[F4]The shares subject to the Option became fully vested and exercisable as of July 1, 2017.

Documents

1 file